Multicenter US Study Reveals CP-GEP’s Profound Impact on Stratifying Melanoma Patients for Long-Term Survival
Source: PR Newswire, November 2023
ROTTERDAM, Netherlands and SAN DIEGO, Nov. 6, 2023 /PRNewswire/ — SkylineDx, an innovative molecular diagnostics company, is pleased to announce the forthcoming presentation of an impactful poster by Dr M.E. Egger at the upcoming Society for Melanoma Research Congress in Philadelphia. Dr. M.E.
Egger’s presentation promises to usher in a new paradigm in disease staging and management for cutaneous melanoma (CM) patients in the United States.
This retrospective study included primary CM patients who underwent sentinel lymph node biopsy (SLNB) at six renowned medical institutions in the United States. The study investigated the performance of the Clinicopathologic and Gene Expression Profile (CP-GEP) model in their patient cohort.
The patients were classified into two distinct categories: high risk and low risk for disease recurrence, offering critical insights into long-term prognosis.